Genitope news from FierceBiotech
NewsGenitope suspends cancer work, looks to alternatives
After reviewing a failed late-stage trial of MyVax for Hodgkins lymphoma, Genitope has decided to suspend development work and focus on alternatives like its antibody program. MyVax had already Read more...
ALSO NOTED: Genitope's MyVax misses Phase III endpoint; Report: Pfizer looks at Danish biotechs; and much more...
> Genitope's MyVax, a treatment for follicular B-cell non-Hodgkin's lymphoma, has flunked a Phase III trial. There was no difference in progression-free survival between patients taking the drug Read more...
Big Pharma takes an interest in cancer vaccines
For two decades, biotech companies have struggled to develop therapeutic cancer vaccines designed to treat the disease by stimulating the immune system to attack cancer cells without harming normal Read more...
| Press ReleasesGenitope Corporation's Vaccine Trial Misses Goal, Stock Drops Genitope Corporation's Vaccine Trial Misses Goal, Stock Drops FREMONT, Calif. -- Genitope Corporation today announced that its pivotal Phase 3 clinical trial examining the use of MyVax® Read more... |
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets